Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Dr Schär S P A has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution means each examiner is responsible for 1 pending action. The involvement of 2 distinct art units suggests the food science or pharmaceutical technologies are categorized in different specialized units. This structure indicates that the company is pursuing multiple technical paths within the sector. The administrative path is defined by these 2 separate units, which affects prosecution timelines and strategy.
LIYUAN MOU is the busiest examiner for the company, with 1 pending office action. With 2 pending office actions and 2 distinct examiners, the workload is split evenly. For the applicant, this means that understanding the specific tendencies of the assigned examiners is a factor for success. The limited scope of 1 pending office action per examiner simplifies the management of the current portfolio. This approach ensures that feedback is filtered through specific professional perspectives across the 2 distinct art units. Consistency in examiner communication is maintained within each of the 2 distinct administrative paths.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| MERRIAM, ANDREW E | 1 | 28.3% | +33.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17782620 | FOOD FORMULATION AND BAKED FOOD PRODUCT FOR MANAGING THE KETOGENIC DIET | MERRIAM, ANDREW E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279807 | LIQUID FOOD PRODUCT TO MANAGE THE KETOGENIC DIET | MOU, LIYUAN | — |
| 17782620 | FOOD FORMULATION AND BAKED FOOD PRODUCT FOR MANAGING THE KETOGENIC DIET | MERRIAM, ANDREW E | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18279807 | LIQUID FOOD PRODUCT TO MANAGE THE KETOGENIC DIET | MOU, LIYUAN | 1628 | §103§112DP | Final Rejection | — | Pending | Aug 31, 2023 |
| 17782620 | FOOD FORMULATION AND BAKED FOOD PRODUCT FOR MANAGING THE KETOGENIC DIET | MERRIAM, ANDREW E | 1791 | §103§112 | Non-Final OA | — | Pending | Jun 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDr Schär S P A has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Liyuan Mou has the most, with 1 of Dr Schär S P A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
